By Jason Shafrin, PhD

The Institute for Clinical and Economic Review (ICER) measures the value of new drugs and health technologies, but faces a number of key challenges such as keeping their assessments up to date with new evidence, allowing for different perspectives on treatment value, and incorporating diverse patient preferences. To address these issues, ICER should follow the lead of the tech industry and start building open source models to measure treatment value.

Read the full article on PharmaPhorum